Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Salesforce Inc (CRM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Salesforce IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Salesforce Inc vs IDEXX Laboratories, Inc. — how do they compare? Salesforce Inc trades at $193.5 (market cap $161.73B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: Salesforce Inc is far larger — about 3.5× IDEXX Laboratories, Inc.'s market cap, and Salesforce Inc pays a 0.89% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

CRMIDXX
Market Cap
$161.73B$46.22B
Sector
TechnologyHealth
52-Week High
$266.23$766.68
52-Week Low
$150.12$526.44
Enterprise Value
$191.77B$47.12B
Dividend Yield
0.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Salesforce Inc

Salesforce (CRM) trades at $192.33, down 2.62% amid broader software sector weakness driven by AI disruption concerns. The stock maintains strong fundamentals with consistent earnings beats, 77.64% gross margins, and 18.73% net income margin. Technical indicators show bullish momentum despite overbought RSI readings, with key support at $193. Analyst consensus remains strongly bullish with a $230.83 price target representing 20% upside potential.

CRM presents a compelling investment case with robust profitability, AI monetization growth, and discounted valuation. Near-term risks include software sector volatility and AI competition, but strong cash flow generation and institutional support provide stability. The current dip offers entry opportunity for long-term investors seeking exposure to enterprise software leadership.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Salesforce Inc

Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.

Read more on CRM

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX